Supira Medical Receives FDA Approval for Pivotal SUPPORT II Study Focusing on Cardiogenic Shock

Supira Medical Advances with FDA Approval of SUPPORT II

Supira Medical, Inc. has officially announced the FDA's approval for its pivotal clinical trial known as SUPPORT II. This trial is aimed at evaluating the effectiveness of the company's next-generation percutaneous ventricular assist device (pVAD) in treating patients experiencing cardiogenic shock during high-risk percutaneous coronary interventions (HRPCI). The approval represents a significant milestone in Supira's journey to revolutionize the market for cardiac support devices.

Key Details of the SUPPORT II Study

The SUPPORT II study will be a prospective, randomized, and controlled trial involving approximately 385 patients across up to 40 clinical sites in the United States. It is led by co-principal investigators Dr. Ajay Kirtane from Columbia University and Dr. David Kandzari from Piedmont Heart Institute. Their expertise is crucial in assessing the safety and efficacy of Supira's innovative pVAD system.

Dr. Kandzari elaborated on the implications for cardiac care, stating, "The decision to utilize hemodynamic support in HRPCI is often impacted by accessibility and the balance between support and procedural efficacy." The introduction of a smaller device capable of providing effective circulatory assistance has the potential to broaden the scope of treatable patients.

Dr. Kirtane added, "Implementing a pVAD allows for the safe execution of complex procedures, thus presenting HRPCI options to patients with previously limited choices. The launch of this randomized pivotal trial is a landmark move toward enhancing care for some of our most vulnerable patients."

Innovations in Treating Cardiogenic Shock

In addition to the SUPPORT II trial, Supira is dedicated to enhancing treatment options for cardiogenic shock patients globally. Recent trials outside the United States demonstrated the successful use of a 10Fr pVAD with axillary access, allowing patient mobility. This advancement emphasizes the potential benefits of mechanical circulatory support, making it more accessible and practical in clinical scenarios.

The ability of cardiologists to offer comprehensive hemodynamic assistance while ensuring patient mobility is shaping the future of care for critically ill individuals suffering from cardiogenic shock.

Leadership Changes at Supira Medical

Alongside these clinical advancements, Supira has appointed D. Keith Grossman as a new independent member of its board of directors. With his extensive 40-year background in medical technology, particularly in mechanical circulatory support, Grossman is expected to be pivotal in shaping Supira's strategies moving forward.

Dr. Nitin Salunke, CEO of Supira Medical, commented on Grossman’s appointment, highlighting his operational discipline, business vision, and strategic insight. “Keith's addition to our board underscores our commitment to building a clinically distinctive organization poised for large-scale operations.”

Grossman remarked, “Supira has laid compelling clinical and technological groundwork that places it in a unique position to transform the growing and still under-penetrated pVAD market.” He expressed excitement about supporting the company as it advances its pivotal trial and prepares to emerge as a leader in treatment options for patients undergoing HRPCI and experiencing cardiogenic shock.

About Supira Medical, Inc.

Supira Medical, a pioneering clinical-stage company, is dedicated to advancing its next-generation pVAD designed for high-risk patients undergoing interventional procedures and experiencing cardiogenic shock. The product has already been utilized in 99 patients, showcasing its efficacy and the company’s commitment to innovative cardiac care. For further insights about Supira Medical, please visit www.supiramedical.com.

In summary, the FDA approval for the SUPPORT II trial marks a pivotal moment for Supira Medical, opening doors to potentially transformative treatments for patients in dire need of effective cardiac intervention.